» Articles » PMID: 39766529

National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study

Abstract

Methods: A total of 182 hospitals participated by submitting Enterobacterales clinical isolates to the National Reference Laboratory (NRL) during the first three weeks of November 2021. Inclusion criteria were defined as an ertapenem MIC ≥ 0.5 mg/L, a zone diameter ≤ 22 mm. Carbapenemase genes and those coding for major extended-spectrum β-lactamases were molecularly characterized using multiplex PCR at the NRL. Antibiotic susceptibility testing followed international standards (CLSI and EUCAST).

Results: The NRL analyzed 821 Enterobacterales isolates. Metallo-β-lactamase (MBL, 42.0%) and KPC (39.8%) accounted for 81.8% of carbapenemases, followed by OXA-163 (7.4%), a variant of OXA-48 with additional activity against extended-spectrum cephalosporins, and enzyme combinations (8.3%). These combinations included NDM plus KPC (3.4%), OXA-163 plus KPC (2.4%), and OXA-163 plus NDM (2.1%). was the main species recovered, representing 76% of the isolates. According to the carbapenemase classes or combinations, tigecycline exhibited a susceptibility range of 33-83%, fosfomycin 59-81%, colistin 27-78%, and amikacin 17-81%. Ceftazidime-avibactam (CZA) and imipenem-relebactam (IMR) showed 92% and 98% susceptibility against serine carbapenemases, respectively. Meanwhile, aztreonam-avibactam (AZA) exhibited 96-98% susceptibility against all carbapenemase classes.

Conclusions: A new epidemiological landscape has emerged, characterized by the equivalent circulation of NDM and KPC. remains the primary species responsible for their dissemination. The co-production of carbapenemase combinations, particularly KPC plus NDM, was confirmed, mainly in . High activity was observed for AZA against MBLs and for CZA and IMR against KPC and OXA-163 carbapenemases.

References
1.
van Duin D, Arias C, Komarow L, Chen L, Hanson B, Weston G . Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis. 2020; 20(6):731-741. PMC: 7473597. DOI: 10.1016/S1473-3099(19)30755-8. View

2.
Safavi M, Bostanshirin N, Hajikhani B, Yaslianifard S, van Belkum A, Goudarzi M . Global genotype distribution of human clinical isolates of New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae; A systematic review. J Glob Antimicrob Resist. 2020; 23:420-429. DOI: 10.1016/j.jgar.2020.10.016. View

3.
Yuan P, Dai L, Zhang Q, Zhong Y, Liu W, Yang L . Global emergence of double and multi-carbapenemase producing organisms: epidemiology, clinical significance, and evolutionary benefits on antimicrobial resistance and virulence. Microbiol Spectr. 2024; 12(7):e0000824. PMC: 11218513. DOI: 10.1128/spectrum.00008-24. View

4.
Faccone D, Gomez S, de Mendieta J, Sanz M, Echegorry M, Albornoz E . Emergence of Hyper-Epidemic Clones of Enterobacterales Clinical Isolates Co-Producing KPC and Metallo-Beta-Lactamases during the COVID-19 Pandemic. Pathogens. 2023; 12(3). PMC: 10052147. DOI: 10.3390/pathogens12030479. View

5.
Timsit J, Paul M, Shields R, Echols R, Baba T, Yamano Y . Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies. Clin Infect Dis. 2022; 75(6):1081-1084. PMC: 9522395. DOI: 10.1093/cid/ciac078. View